Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment.
Aged
Alzheimer Disease
/ blood
Biomarkers
/ blood
Cognitive Dysfunction
/ psychology
Diagnosis, Differential
Female
Frontotemporal Dementia
/ blood
Glial Fibrillary Acidic Protein
/ blood
Humans
Lewy Body Disease
/ blood
Male
Mental Status and Dementia Tests
Middle Aged
Parkinson Disease
/ blood
Pilot Projects
Sensitivity and Specificity
Alzheimer’s disease
GFAP
Lewy body dementia
Parkinson’s disease
astrocyte
biomarker
cerebrospinal fluid
differential diagnosis
frontotemporal dementia
serum
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
31
12
2018
medline:
3
3
2020
entrez:
31
12
2018
Statut:
ppublish
Résumé
Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r= -0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.
Identifiants
pubmed: 30594925
pii: JAD180325
doi: 10.3233/JAD-180325
doi:
Substances chimiques
Biomarkers
0
GFAP protein, human
0
Glial Fibrillary Acidic Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM